N-terminus of flagellin enhances vaccine efficacy against Actinobacillus pleuropneumoniae

BMC Vet Res. 2022 Jul 16;18(1):279. doi: 10.1186/s12917-022-03380-8.

Abstract

Background: Flagellin elicits potent immune response and may serve as a vaccine adjuvant. We previously reported that the N-terminus of flagellin (residues 1-99, nFliC) is sufficient for vaccine efficacy enhancement against Pasteurella multocida challenge in chickens. In this study, we futher tested the adjuvancy of nFliC in a subunit vaccine against the pig pathogen Actinobacillus pleuropneumoniae in a mice model. For vaccine formulation, the antigen ApxIIPF (the pore-forming region of the exotoxin ApxII) was combined with nFliC, either through genetic fusion or simple admixture.

Results: Immune analysis showed that nFliC, introduced through genetic fusion or admixture, enhanced both humoral (antibody levels) and cellular (T cell response and cytokine production) immunity. In a challenge test, nFliC increased vaccine protective efficacy to 60-80%, vs. 20% for the antigen-only group. Further analysis showed that, even without a supplemental adjuvant such as mineral salt or oil emulsion, genetically linked nFliC still provided significant immune enhancement.

Conclusions: We conclude that nFliC is a versatile and potent adjuvant for vaccine formulation.

Keywords: Actinobacillus pleuropneumoniae; Adjuvant; Flagellin; Pore-forming toxins.

MeSH terms

  • Actinobacillus Infections* / prevention & control
  • Actinobacillus Infections* / veterinary
  • Actinobacillus pleuropneumoniae*
  • Animals
  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Chickens
  • Flagellin
  • Mice
  • Swine
  • Swine Diseases* / prevention & control
  • Vaccine Efficacy

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Flagellin